IL6 and stroke disorder: The subgroup analysis of our study showed that the anti-inflammatory drugs targeting the central IL-6 inflammatory signaling pathway can reduce the incidence of primary outcome (composite outcome of cardiovascular death, MI, or stroke), as well as the risk of MI and coronary revascularization.